EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Developing New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response

Thomas J Moore iD, Mariana P Socal iD, Gerard Anderson iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Thomas J Moore und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Drug Development, COVID-19 Drug Treatment, COVID-19, Drugs, Investigational. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

To meet the need for effective treatments during the COVID‐19 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments—a process that normally took 4–12 years. The government changed many features of the established system, selecting the investigational drugs, sponsoring or conducting the clinical testing, and purchasing and managing the distribution of the successful products.

Methods

We focused on novel therapeutic agents for COVID‐19 that were funded, clinically tested, and/or received Emergency Use Authorization during the Public Health Emergency from January 2020 to May 2023. The primary sources were the public records of the National Institutes of Health, the U.S. Food and Drug Administration, and the Biomedical Advanced Research and Development Authority. Excluded were vaccines, devices, diagnostic tests, and new indications for approved drugs.

Results

In less than 24 months, the emergency program developed, tested, approved, and distributed eight new therapeutic products, including six monoclonal antibodies and two new oral antivirals. In addition, 11 other investigational agents were funded or tested under the emergency program but did not receive Emergency Use Authorization. More than 30 million courses of treatment were distributed at a cost of $29 billion or $881 per patient. By the end of the emergency, viral mutations and rapidly growing population immunity rendered the new products ineffective in almost all patients.

Conclusions

The emergency program was dramatically effective in finding and testing new drug treatments using a variety of clinically relevant endpoints and serving varied patient populations. Planning for future pandemics should include a global network of clinical testing centers that were key to a rapid response. Research is needed to discover more durable antiviral treatments, especially in settings where mutation and population immunity are subject to rapid change.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentCOVID-19 Drug TreatmentCOVID-19Drugs, InvestigationalAntiviral AgentsHumansUnited StatesUnited States Food and Drug AdministrationEmergency Use AuthorizationAntibodies, MonoclonalSARS-CoV-2MutationPandemic PreparednessPandemics

Stichwörter der Autor:innen

COVID‐19 drug treatmentSARS‐CoV‐2coronavirusdrug approval/organization and administrationdrug development/organization and administrationdrug research and development

Substanzen

Drugs, InvestigationalAntiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Thomas J Moore, Mariana P Socal, Gerard Anderson

Zitieren

APA

Moore, T. J., Socal, M. P., & Anderson, G. (2025). Developing New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70070

Vancouver

Moore TJ, Socal MP, Anderson G. Developing New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70070

BibTeX
@article{Moore2025,
  author = {Moore, Thomas J and Socal, Mariana P and Anderson, Gerard},
  title = {Developing New Drugs for the COVID ‐19 Emergency: Anatomy of the U.S. Response},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70070}
}
Kostenlos starten →